1. Signaling Pathways
  2. Apoptosis
  3. RIP kinase

RIP kinase

Receptor interacting protein 2 (RIP2), a serine/threonine kinase, is an adaptor molecule of NOD1 and NOD2, and genetic variation in this receptor is known to be associated with the severity of allergic asthma in children.

Receptor interacting protein kinase 2 (RIPK2) is critical for NOD-mediated NF-κB activation and cytokine production. WEHI-345, a selective RIPK2 kinase inhibitor, which delays RIPK2 ubiquitylation and NF-κB activation downstream of NOD engagement.

Receptor interacting protein kinase 3 (RIPK3) is a cytosolic master regulator of necroptosis. RIPK3 has an active serine/threonine kinase domain at the N-terminus, and a unique protein-protein interaction domain called the RIP homotypic interaction motif (RHIM) at the C-terminus. Both kinase activity and RHIM are indispensable for necroptosis. RIPK3 interacts with other RHIM-containing proteins such as RIPK1, Toll/interleukin-1 (IL-1) receptor domain-containing adaptor protein inducing TRIF or DAI. RIPK3 induces necroptosis, a type of regulated necrosis, through its kinase domain and RHIM.

RIP kinase Related Products (30):

Cat. No. Product Name Effect Purity
  • HY-15760
    Necrostatin-1 Inhibitor 99.20%
    Necrostatin-1 (Nec-1) is a potent, selective and cell-permeable necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 acts by inhibiting (RIP1) kinase domain in the necroptosis pathway.
  • HY-101872
    GSK-872 Inhibitor 99.65%
    GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM.
  • HY-101760
    GSK2982772 Inhibitor >98.0%
    GSK2982772 is an orally, potent and ATP competitive RIP1 kinase inhibitor with IC50 values of 16 nM and 20 nM for human and monkey RIP1, respectively.
  • HY-101032
    RIPA-56 Inhibitor 99.86%
    RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome.
  • HY-14622
    Necrostatin 2 Inhibitor 99.97%
    Necrostatin 2 is a potent necroptosis inhibitor. EC50 for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor.
  • HY-104021
    GSK840 Inhibitor >98.0%
    GSK840 (GSK'840) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 0.9 nM, and inhibits kinase activity with an IC50 of 0.3 nM.
  • HY-125402
    GSK-843 Inhibitor >98.0%
    GSK-843 (GSK'843) is a receptor-interacting protein kinase 3 (RIP3 or RIPK3) inhibitor, which binds RIP3 kinase domain with an IC50 of 8.6 nM, and inhibits kinase activity with an IC50 of 6.5 nM.
  • HY-122909
    GSK2593074A Inhibitor
    GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3.
  • HY-100339
    GSK583 Inhibitor 98.64%
    GSK583 is a highly potent, orally active and selective inhibitor of RIP2 Kinase, with IC50 of 5 nM. GSK583 inhibits both TNF-α and IL-6 production with an IC50 value of 200 nM.
  • HY-18937
    WEHI-345 Inhibitor 99.27%
    WEHI-345 is a potent and selective inhibitor of RIPK2, with IC50 of 0.13 μM.
  • HY-14622A
    Necrostatin 2 racemate Inhibitor 99.10%
    Necrostatin 2 racemate is a potent necroptosis inhibitor, acts as a RIPK1 inhibitor lacking the IDO-targeting effect.
  • HY-19764
    RIP2 kinase inhibitor 1 Inhibitor 98.24%
    RIP2 kinase inhibitor 1 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043446 A1, compound example 1.
  • HY-19761
    RIP2 kinase inhibitor 2 Inhibitor 99.95%
    RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9.
  • HY-100131
    GSK'481 Inhibitor >98.0%
    GSK'481 (GSK481) is a potent, selective, and specific RIP1 inhibitor (IC50=1.3 nM), which inhibits Ser166 phosphorylation in wild-type human RIP1 (IC50=2.8 nM). GSK'481 (GSK481) inhibits Ser166 phosphorylation in three mouse RIP1 mutants (IC50=18~110 nM) more potently than in wild-type mouse. GSK'481 exhibits selectivity for RIP1 over >450 kinases.
  • HY-14622B
    Necrostatin 2 S enantiomer Inhibitor 99.83%
    Necrostatin 2 S enantiomer is the S enantiomer of Necrostatin 2.
  • HY-114349
    HS-1371 Inhibitor 98.49%
    HS-1371 is a potent and ATP-competitive receptor-interacting protein kinase 3 (RIP3) inhibitor with an IC50 of 20.8 nM.
  • HY-114492
    GSK547 Inhibitor 99.33%
    GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIP1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer.
  • HY-111946
    GSK3145095 Inhibitor 98.27%
    GSK3145095 is a RIP1 kinase inhibitor with an IC50 of 6.3 nM .
  • HY-112038A
    GSK2983559 Inhibitor
    GSK2983559 (compound 3) is a potent, specific and oral bioavailable receptor interacting protein 2 (RIP2) kinase inhibitor, which has excellent activity in blocking many proinflammatory cytokine responses in vivo and in human inflammatory bowel disease explant samples.
  • HY-112907
    RIP2 Kinase Inhibitor 3 Inhibitor
    RIP2 Kinase Inhibitor 3 is a highly potent and selective inhibitor of receptor interacting protein-2 (RIP2) Kinase with an IC50 of 1 nM .
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.